Management of community-acquired pneumonia in HIV-infected children

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 4, 2009, Pages 437-451

  Gray, Diane ^a   Zar, Heather J ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Acute respiratory infectious; Children; Community acquired; HIV; Pneumonia; Treatment

Indexed keywords

ACICLOVIR; AMOXICILLIN; AMPHOTERICIN B; AMPICILLIN; ANTIRETROVIRUS AGENT; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CLOXACILLIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; ETHIONAMIDE; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; ISONIAZID; ITRACONAZOLE; OSELTAMIVIR; PENICILLIN G; PENTAMIDINE; PREDNISONE; PYRAZINAMIDE; RETINOL; RIFAMPICIN; STREPTOMYCIN; UNINDEXED DRUG; VALGANCICLOVIR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANEMIA; BACTERIAL PNEUMONIA; CHILD; CHILD CARE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CRYPTOCOCCOSIS; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; ERYTHEMA MULTIFORME; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION PREVENTION; INTERSTITIAL NEPHRITIS; LUNG MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; OXYGEN THERAPY; PNEUMOCYSTIS PNEUMONIA; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TUBERCULOSIS; VIRUS PNEUMONIA; AIDS RELATED COMPLEX; CASE MANAGEMENT; COMMUNICABLE DISEASE; LUNG TUBERCULOSIS; PNEUMONIA; PRACTICE GUIDELINE; VACCINATION; WORLD HEALTH ORGANIZATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE MANAGEMENT; CHILD; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; LUNG DISEASES, FUNGAL; PNEUMONIA; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; PNEUMONIA, VIRAL; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS, PULMONARY; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 67650134098     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.14     Document Type: Review

References (129)

1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO estimates of the causes of death in children. Lancet 365(9465), 1147-1152 (2005).
2. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect. Dis. 2(1), 25-32 (2002).
3. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull. World Health Organ. 82(12), 895-903 (2004).
4. Morris SS, Black RE, Tomaskovic L. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. Int. J. Epidemiol. 32(6), 1041-1051 (2003).
5. Mulholland K. Magnitude of the problem of childhood pneumonia. Lancet 354(9178), 590-592 (1999).
6. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull. World Health Organ. 86(5), 408-416 (2008).
7. Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet 361 (9359), 763-773 (2003).
8. Ahmad OB, Lopez AD, Inoue M. The decline in child mortality: a reappraisal. Bull. World Health Organ. 78(10), 1175-1191 (2000).
9. Graham SM. Impact of HIV on childhood respiratory illness: differences between developing and developed countries. Pediatr. Pulmonol. 36(6), 462-468 (2003).
10. Graham SM, Mtitimila EI, Kamanga HS, Walsh AL, Hart CA, Molyneux ME. Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children. Lancet 355(9201), 369-373 (2000).
11. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin. Infect. Dis. 31(1), 170-176 (2000).
12. Jeena PM, Pillay P, Pillay T, Coovadia HM. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int. J. Tuberc. Lung Dis. 6(8), 672-678 (2002).
13. Zar HJ, Hanslo D, Tannenbaum E et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa Acta Paediatr. 90(2), 119-125 (2001).
14. McNally LM, Jeena PM, Gajee K et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 369(9571), 1440-1451 (2007).
15. Graham SM, Coulter JB, Gilks CF. Pulmonary disease in HIV-infected African children. Int. J. Tuberc. Lung Dis. 5(1), 12-23 (2001).
16. Graham SM. HIV and respiratory infections in children. Curr. Opin. Pulm. Med. 9(3), 215-220 (2003).
17. Ikeogu MO, Wolf B, Mathe S. Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Arch. Dis. Child. 76(2), 124-128 (1997).
18. Lucas SB, Peacock CS, Hounnou A et al. Disease in children infected with HIV in Abidjan, Cote d'Ivoire. BMJ 312(7027), 335-338 (1996).
19. Zar HJ, Apolles P, Argent A et al. The etiology and outcome of pneumonia in human immunodeficiency virus-infected children admitted to intensive care in a developing country. Pediatr. Crit. Care Med. 2(2), 108-112 (2001).
20. Williams AJ, Duong T, McNally LM et al. Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. AIDS 15(3), 335-339 (2001).
21. Jeena PM, Coovadia HM, Chrystal V. Pneumocystis carinii and cytomegalovirus infections in severely ill, HIV-infected African infants. Ann. Trop. Paediatr. 16(4), 361-368 (1996).
22. Chintu C, Mudenda V, Lucas S et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 360(9338), 985-990 (2002).
23. Cotton MF, Wasserman E, Smit J, Whitelaw A, Zar HJ. High incidence of antimicrobial resistant organisms including extended spectrum β-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect. Dis. 8, 40 (2008).
24. Gona P, Van Dyke RB, Williams PL et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 296(3), 292-300 (2006).
25. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr. 8, 1 (2008).
26. Zachariah R, Harries AD, Luo C, Bachman G, Graham SM. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. Lancet Infect. Dis. 7(10), 686-693 (2007).
27. Antiretroviral therapy for children in the routine setting in Malawi. Trans. R. Soc. Trop. Med. Hyg. 101(5), 511-516 (2007).
28. Boulle A, Bock P, Osler M et al. Antiretroviral therapy and early mortality in South Africa. Bull. World Health Organ. 86(9), 678-687 (2008).
29. Berdon WE, Mellins RB, Abramson SJ, Ruzal-Shapiro C. Pediatric HIV infection in its second decade - the changing pattern of lung involvement. Clinical, plain film, and computed tomographic findings. Radiol. Clin. North Am. 31(3), 453-463 (1993).
30. Norton KI, Kattan M, Rao JS et al. Chronic radiography lung changes in children with vertically transmitted HIV-1 infection. AJR Am. J. Roentgenol. 176(6), 1553-1558 (2001).
31. Zar HJ. Chronic lung disease in human immunodeficiency virus (HIV) infected children. Pediatr. Pulmonol. 43(1), 1-10 (2008).
32. Shann F. Etiology of severe pneumonia in children in developing countries Pediatr. Infect. Dis. J. 5, 247-251 (1986).
33. Adegbola RA, Falade AG, Sam BE et al. The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr. Infect. Dis. J. 13(11), 975-982 (1994).
34. Berkley JA, Maitland K, Mwangi I et al. Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ 330 (7498), 995 (2005).
35. Graham SM, Molyneux EM, Walsh AL, Cheesbrough JS, Molyneux ME, Hart CA. Nontyphoidal Salmonella infections of children in tropical Africa. Pediatr. Infect. Dis. J. 19(12), 1189-1196 (2000).
36. Berkley JA, Lowe BS, Mwangi I et al. Bacteremia among children admitted to a rural hospital in Kenya. N. Engl. J. Med. 352(1), 39-47 (2005).
37. Mulholland K, Hilton S, Adegbola R et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 349(9060), 1191-1197 (1997).
38. Levine OS, Lagos R, Munoz A et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr. Infect. Dis. J. 18(12), 1060-1064 (1999).
39. Baqui AH, El Arifeen S, Saha SK et al. Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case - control study. Pediatr. Infect. Dis. J. 26(7), 565-571 (2007).
40. de la Hoz F, Higuera AB, Di Fabio JL et al. Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine 23(1), 36-42 (2004).
41. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr. Infect. Dis. J. 19(12), 1141-1147 (2000).
42. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr. Opin. Infect. Dis. 20(1), 11-15 (2007).
43. Bliss SJ, O'Brien KL, Janoff EN et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect. Dis. 8(1), 67-80 (2008).
44. Coovadia HM, Jeena P, Wilkinson D. Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Int. J. Tuberc. Lung Dis. 2(10), 844-851 (1998).
45. Schaaf HS, Marais BJ, Whitelaw A et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect. Dis. 7, 140 (2007).
46. Mukadi YD, Wiktor SZ, Coulibaly IM et al. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cote d 'Ivoire. AIDS 11(9), 1151-1158 (1997).
47. Palme IB, Gudetta B, Bruchfeld J, Muhe L, Giesecke J. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr. Infect. Dis. J. 21(11). 1053-1061 (2002).
48. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 270(4), 470-473 (1993).
49. Ansari NA, Kombe AH, Kenyon TA et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana. Pediatr. Infect. Dis. J. 22(1), 43-47 (2003).
50. Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann. Trop. Paediatr. 24(3), 227-235 (2004).
51. Madhi SA, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman KP. Ineffectiveness of trimethoprim - sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin. Infect. Dis. 35(9), 1120-1126 (2002).
52. Wijesingha S, Graham S. Evidence behind the WHO guidelines: hospital care for children. What are the clinical indicators of PCP? J. Trop. Pediatr. 53(1), 4-7 (2007).
53. Graham SM. Non-tuberculosis opportunistic infections and other lung diseases in HIV-infected infants and children. Int. J. Tuberc. Lung Dis. 9(6), 592-602 (2005).
54. Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J. Pediatr. 137(1), 78-84 (2000).
55. Madhi SA, Ramasamy N, Bessellar TG, Saloojee H, Klugman KP. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr. Infect. Dis. J. 21(4), 291-297 (2002).
56. Madhi SA, Ramasamy N, Petersen K, Madhi A, Klugman KP. Severe lower respiratory tract infections associated with human parainfluenza viruses 1-3 in children infected and noninfected with HIV type 1. Eur. J. Clin. Microbiol. Infect. Dis. 21(7), 499-505 (2002).
57. Madhi SA, Venter M, Madhi A, Petersen MK, Klugman KP. Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children. Pediatr. Infect. Dis. J. 20(2), 164-170 (2001).
58. Forgie IM, O'Neill KP, Lloyd-Evans N et al. Etiology of acute lower respiratory tract infections in Gambian children: II. Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital. Pediatr. Infect. Dis. J. 10(1), 42-47 (1991).
59. Forgie IM, O'Neill KP, Lloyd-Evans N et al. Etiology of acute lower respiratory tract infections in Gambian children: I. Acute lower respiratory tract infections in infants preseating at the hospital. Pediatr. Infect. Dis. J. 10(1), 33-41 (1991).
60. Madhi SA, Ludewick H, Kuwanda L et al. Pneumococcal coinfection with human metapneumovirus. J. Infect. Dis. 193(9), 1236-1243 (2006).
61. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 10(8), 811-813 (2004).
62. Mofenson LM, Oleske J, Serchuck L, Van Dyke R, Wilfert C. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Clin. Infect. Dis. 40(Suppl. 1), S1-S84 (2005).
63. Lucas SB, Peacock CS, Hounnou A et al. Disease in children infected with HIV in Abidjan, Cote d'Ivoire. BMJ 312(312), 335-338 (1996).
64. Dudley L, Hussey G, Huskissen J, Kessow G. Vitamin A status, other risk factors and acute respiratory infection morbidity in children. S. Afr. Med. J. 87(1), 65-70 (1997).
65. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N. Engl. J. Med. 323(3), 160-164 (1990).
66. Graham SM, English M, Hazir T, Enarson P, Duke T. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. Bull. World Health Organ. 86(5), 349-355 (2008).
67. Pio A. Standard case management of pneumonia in children in developing countries: the cornerstone of the acute respiratory infection programme. Bull. World Health Organ. 81(4), 298-300 (2003).
68. Sazawal S, Black RE. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet Infect. Dis. 3(9), 547-556 (2003).
69. Qazi SA, Rehman GN, Khan MA. Standard management of acute respiratory infections in a children's hospital in Pakistan: impact on antibiotic use and case fatality. Bull. World Health Organ. 74(5), 501-507 (1996).
70. Marsh DR, Gilroy KE, Van de Weerdt R, Wansi E, Qazi S. Community case management of pneumonia: at a tipping point? Bull. World Health Organ. 86(5), 381-389 (2008).
71. Duke T, Wandi F, Jonathan M et al. Improved oxygen systems for childhood pneumonia: a multihospital effectiveness study in Papua New Guinea. Lancet 372(9646), 1328-1333 (2008).
72. Roth DE, Caulfield LE, Ezzati M, Black RE. Acute lower respiratory infections in childhood: opportunities for reducing the global burden through nutritional interventions. Bull. World Health Organ. 86(5), 356-364 (2008).
73. Cardoso MR, Nascimento-Carvalho CM, Ferrero F et al. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch. Dis. Child. 93(3), 221-225 (2008).
74. Addo-Yobo E, Chisaka N, Hassan M et al. Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study. Lancet 364(9440), 1141-1148 (2004).
75. Jeena P, Thea DM, MacLeod WB et al. Failure of standard antimicrobial therapy in children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia. Bull. World Health Organ. 84(4), 269-275 (2006).
76. Graham SM. HIV-related pulmonary disorders: practice issues. Ann. Trop. Paediatr. 27(4), 243-252 (2007).
77. Hazir T, Fox LM, Nisar YB et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet 371(9606), 49-56 (2008).
78. Gutman LT, Moye J, Zimmer B, Tian C. Tuberculosis in human immunodeficiency virus-exposed or -infected United States children. Pediatr. Infect. Dis. J. 13(11), 963-968 (1994).
79. Schaaf HS, Geldenduys A, Gie RP, Cotton MF. Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children. Pediatr. Infect. Dis. J. 17(7), 599-604 (1998).
80. Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 24(8), 685-691 (2005).
81. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50(2), 407-413 (2006).
82. Schaaf HS, Parkin DP, Seifart HI et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child. 90(6), 614-618 (2005).
83. Hill S, Regondi I, Grzemska M, Matiru R. Children and tuberculosis medicines: bridging the research gap. Bull. World Health Organ. 86(9), 658 (2008).
84. Donald PR, Schaaf HS. Old and new drugs for the treatment of tuberculosis in children. Paediatr. Respir. Rev. 8(2), 134-141 (2007).
85. Red Book: 2006 report of the Committee on Infectious Diseases. Pickering LK (Ed.) American Academy of Pediatrics, Elk Grove Village, IL, USA (2006).
86. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364(9441), 1244-1251 (2004).
87. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr. Infect. Dis. J. 25(1), 53-58 (2006).
88. Bonnet MM, Pinoges LL, Varaine FF et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 20(9), 1275-1279 (2006).
89. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int. J. Tuberc. Lung Dis. 11(4), 417-423 (2007).
90. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis. 5(6), 361-373 (2005).
91. Gutman LT. The use of trimethaprom-sulfamethoxazole in children: a review of adverse reactions and indications. Pediatr. Infect Dis. J. 3, 349-357 (1984).
92. Rieder MJ, King SM, Read S. Adverse reactions to trimethoprim - sulfamethoxazole among children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 16(11), 1028-1031 (1997).
93. Zar HJ, Alvarez-Martinez MJ, Harrison A, Meshnick SR. Prevalence of dihydropteroate synthase mutants in HIV-infected South African children with Pneumocystis jiroveci pneumonia. Clin. Infect. Dis. 39(7), 1047-1051 (2004).
94. Kazanjian P, Locke AB, Hossler PA et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12(8), 873-878 (1998).
95. Bye MR, Cairns-Bazarian AM, Ewig JM. Markedly reduced mortality associated with corticosteroid therapy of Pneumocystis carinii pneumonia in children with acquired immunodeficiency syndrome. Arch. Pediatr. Adolesc. Med. 148(6), 638-641 (1994).
96. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst. Rev. 3, CD006150 (2006).
97. McLaughlin GE, Virdee SS, Schleien CL, Holzman BH, Scott GB. Effect of corticosteroids on survival of children with acquired immunodeficiency syndrome and Pneumocystis carinii-related respiratory failure. J. Pediatr. 126(5 Pt 1), 821-824 (1995).
98. Frenkel LD, Gaur S, Tsolia M, Scudder R, Howell R, Kesarwala H. Cytomegalovirus infection in children with AIDS. Rev. Infect. Dis. 12(Suppl. 7), S820-S826 (1990).
99. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 658-661 (2000).
100. Duke T, Mgone J, Frank D. Hypoxaemia in children with severe pneumonia in Papua New Guinea. Int. J. Tuberc. Lung Dis. 5(6), 511-519 (2001).
101. Lozano JM. Epidemiology of hypoxaemia in children with acute lower respiratory infection. Int. J. Tuberc. Lung Dis. 5(6), 496-504 (2001).
102. Matai S, Peel D, Wandi F, Jonathan M, Subhi R, Duke T. Implementing an oxygen programme in hospitals in Papua New Guinea. Ann. Trop. Paediatr. 28(1), 71-78 (2008).
103. Enarson P, La Vincente S, Gie R, Maganga E, Chokani C. Implementation of an oxygen concentrator system in district hospital paediatric wards throughout Malawi. Bull. World Health Organ. 86(5), 344-348 (2008).
104. Zar HJ. Prevention of HIV-associated respiratory illness in children in developing countries: potential benefits. Int. J. Tuberc. Lung Dis. 7(9), 820-827 (2003).
105. Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29(5), 484-494 (2002).
106. Faye A, Le Chenadec J, Dollfus C et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin. Infect. Dis. 39(11), 1692-1698 (2004).
107. Violari A, Cotton MF, Gibb D. Antiretroviral therapy initiated before 12 weeks of age reduces mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. In: 4th International AIDS Society Conference on Pathogenesis, Treatment and Prevention. Sydney, Australia, 23 July 2007.
108. Zar HJ, Hanslo D, Hussey G. The impact of HIV infection and trimethoprim - sulphamethoxazole prophylaxis on bacterial isolates from children with community-acquired pneumonia in South Africa. J. Trop. Pediatr. 49(2), 78-83 (2003).
109. Chintu C, Bhat GJ, Walker AS et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 364(9448), 1865-1871 (2004).
110. Barnett ED, Pelton SI, Mirochnick M, Cooper ER. Dapsone for prevention of Pneumocystis pneumonia in children with acquired immunodeficiency syndrome. Pediatr. Infect. Dis. J. 13(1), 72-74 (1994).
111. Cruciani M, Concia E, Gatti G, Fioredda F, Bassetti D. Dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 13(1), 80-81 (1994).
112. Orcutt TA, Godwin CR, Pizzo PA, Ognibene FP. Aerosolized pentamidine: a well-tolerated mode of prophylaxis against Pneumocystis carinii pneumonia in older children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 11(4), 290-294 (1992).
113. Hand IL, Wiznia AA, Porricolo M, Lambert G, Caspe WB. Aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in infants with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 13(2), 100-104 (1994).
114. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. 2, CD001363 (2000).
115. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 1, CD000171 (2004).
116. Zar HJ, Cotton MF, Strauss S et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 334(7585), 136 (2007).
117. King JC Jr, Vink PE, Farley JJ, Smilie M, Parks M, Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 99(4), 575-580 (1997).
118. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349(14), 1341-1348 (2003).
119. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin. Infect. Dis. 40(10), 1511-1518 (2005).
120. Zar HJ, Madhi SA. Pneumococcal conjugate vaccine - a health priority. S. Afr. Med. J. 98(6), 463-467 (2008).
121. Flannery B, Heffernan RT, Harrison LH et al. Changes in invasive Pneumococcal disease-among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann. Intern. Med. 144(1), 1-9 (2006).
122. Madhi SA, Levine OS, Hajjeh R, Mansoor OD, Cherian T. Vaccines to prevent pneumonia and improve child survival. Bull. World Health Organ. 86(5), 365-372 (2008).
123. Madhi SA, Petersen K, Khoosal M et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr. Infect. Dis. J. 21(4), 315-321 (2002).
124. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect. Dis. 4(8), 510-518 (2004).
125. Allison MA, Daley MF, Crane LA et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J. Pediatr. 149(6), 755-762 (2006).
126. Periquet BA, Jammes NM, Lambert WE et al. Micronutrient levels in HIV-1-infected children. AIDS 9(8), 887-893 (1995).
127. Bhutta ZA, Black RE, Brown KH et al. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J. Pediatr. 135(6), 689-697 (1999).
128. Dherani M, Pope D, Mascarenhas M, Smith KR, Weber M, Bruce N. Indoor air pollution from unprocessed solid fuel use and pneumonia risk in children aged under five years: a systematic review and meta-analysis. Bull. World Health Organ. 86(5), 390C-398C (2008).
129. World Health Organisation. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO, Geneva, Switzerland (2006).